Article thumbnail

Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study

By Jonathan H Williams, Gordon K Wilcock, Jeffrey Seeburger, Aimee Dallob, Omar Laterza, William Potter and A David Smith
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3109414
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2000). A plasticity-based theory of the pathogenesis of Alzheimer’s disease.
  2. (1986). A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia.
  3. (1997). Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray Williams et al.
  4. (1999). Alois Alzheimer and the amyloid debate. Nature
  5. (2007). Alzheimer’ s disease, oxidative stress and gammahydroxybutyrate. Neurobiol Aging
  6. (2005). Alzheimer’s Disease International: Global prevalence of dementia: a Delphi consensus study. Lancet
  7. (2009). Alzheimer’s Disease: A Multicenter Assessment. J Nutr Health Aging
  8. (2007). Alzheimer’s disease: progress in the development of anti-amyloid disease-modifying therapies. CNS Spectr
  9. (1995). AM: High acceptability and low morbidity of diagnostic lumbar puncture in elderly subjects of mixed cognitive status. Acta Neurol Scand
  10. (2006). Amyloid beta: the alternate hypothesis. Curr Alzheimer Res
  11. (2005). APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology
  12. (2008). Arrighi HM: Worldwide variation in the doubling time of Alzheimer’s disease incidence rates. Alzheimers Dement
  13. (2002). BD: Modern Applied Statistics with S. 4 edition.
  14. (2008). Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood. Mol Diagn Ther
  15. (2010). Blennow K: Confounding factors influencing amyloid beta concentration in cerebrospinal fluid.
  16. (2005). Blennow K: CSF biomarkers for mild cognitive impairment and early Alzheimer’sd i s e a s e .Clin Neurol Neurosurg
  17. (2007). Blennow K: Prediction of Alzheimer’s disease using the CSF Abeta42/ Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord
  18. (1997). Braak E: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging
  19. (2002). C: strucchange: An R package for testing for structural change in linear regression models.
  20. (2001). Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer’s disease. Exp Neurol
  21. (2004). Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx
  22. (2008). Conversion from cognitive health to mild cognitive impairment and Alzheimer’s disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging
  23. (2008). Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing
  24. (2003). Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA
  25. (2006). Diagnostic criteria in dementia: a comparison of current criteria, research challenges, and implications for DSM-V.
  26. (2007). Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology
  27. (2008). Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol
  28. (1984). EM: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’sD i s e a s e .Neurology
  29. (2002). et al: Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol Aging
  30. (2008). Forlenza OV: Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and metaanalysis of the literature.
  31. (2007). Grundke-Iqbal I: Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci
  32. (2002). H: CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology
  33. (2006). Has the amyloid cascade hypothesis for Alzheimer’s disease been proved? Curr Alzheimer Res
  34. (1999). Hedley-Whyte ET: Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease.
  35. (2006). Humpel C: Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dement Geriatr Cogn Disord
  36. ifultools: Insightful Research Tools.
  37. (2000). Imahori K: CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol
  38. (2005). Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment. Neurosci Lett
  39. (2005). JB: Evaluation of selection bias in an incident-based dementia autopsy case series. Alzheimer Dis Assoc Disord
  40. (2009). JC: Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging
  41. (1997). JH: Neuropathological assessment of the lesions of significance in vascular dementia.
  42. (2010). JQ: Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol
  43. (2004). Jr: Back to the future: the ‘old-fashioned’ way to new medications for neurodegeneration. Nat Med
  44. (2008). Kienzl E: Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’–a new blood biomarker? J Cell Mol Med
  45. (1991). L: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology
  46. (2007). Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch Gen Psychiatry
  47. (2005). Markesbery W: Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study.
  48. (2007). Mevik B-H: ffmanova: Fifty-fifty MANOVA.
  49. (2006). Mild cognitive impairment and the 7 uses of epidemiology. Alzheimer Dis Assoc Disord
  50. (2006). Minghetti L: Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer’s disease.
  51. (2006). Minthon L: Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol
  52. (1996). Munroe WA: Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer’s disease.
  53. (2010). Nonspecific binding of Ab42 to polypropylene tubes and the effect of Tween-20. Clin Chimica Acta
  54. (2008). of 11effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet
  55. (2005). Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology
  56. (2009). Rapid progression from mild cognitive impairment to Alzheimer’s disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/ epsilon4 genotype. Dement Geriatr Cogn Disord
  57. (2006). Reboldi P: Diagnosing prodromal Alzheimer’s disease: role of CSF biochemical markers. Mech Ageing Dev
  58. (2008). Shifts in thinking about dementia. JAMA
  59. (2009). subjects: diagnostic discrimination and cognitive correlations. Neurology
  60. (2003). Trojanowski JQ: Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsyconfirmed dementia diagnoses? Arch Neurol
  61. (2008). Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc
  62. (2004). Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatry
  63. (2009). van der Flier WM: CSF biomarker levels in early and late onset Alzheimer’s disease. Neurobiol Aging
  64. (2009). van der Flier WM: CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology
  65. (2007). Younkin SG: Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol